Evolocumab-Associated Hemorrhagic Pericarditis With Cardiac Tamponade: Case Report

Clicks: 1
ID: 315590
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #234 of 251 articles by views in European Heart Journal - Case Reports

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 251 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Evolocumab, a fully humanized monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), is one of the most widely used lipid-lowering therapies for atherosclerotic cardiovascular disease (ASCVD). It is generally well-tolerated, but immune-mediated inflammatory reactions may occur with monoclonal antibodies. Among common adverse effects associated with evolocumab, pericardial disease associated with PCSK9 inhibitors is extremely rare. Case Presentation A man in the late 70s on evolocumab for two months presented to the hospital for atrial flutter and moderate pericardial effusion. He was treated with amiodarone and discharged with colchicine and indomethacin. Ten days later, the patient represented with worsening shortness of breath, malaise, and jugular venous distension with echocardiographic evidence of tamponade physiology. Emergent pericardiocentesis drained about one liter of sanguineous fluid. Autoimmune, infectious, and malignant etiologies were systematically excluded. Evolocumab was discontinued, and the patient remained asymptomatic without recurrence. Discussion This case illustrates a probable immune-mediated pericarditis with hemorrhagic effusion and tamponade seen with evolocumab use. Clinicians should remain vigilant for this rare monoclonal antibody–associated pericardial inflammation as a potentially serious adverse reaction to evolocumab, particularly when other common causes have been excluded. Continued pharmacovigilance is essential as the use of PCSK9 inhibitors expands.
Reference Key
openalex_W7163206550 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Aaron Y Kim, Laura Bradel, Nimrah Hossain, Brian Wong
Journal European Heart Journal - Case Reports
Year 2026
DOI
10.1093/ehjcr/ytag403
URL
https://doi.org/10.1093/ehjcr/ytag403
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.